Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Response rate according to systemic treatment
| Response rate | Systemic chemotherapy+ cetuksimab, number (%) | Systemic chemotherapy+ bevacizumab, number (%) |
|---|---|---|
| Complete response | 7 (13) | 6 (17) |
| Partial response | 18 (34) | 8 (23) |
| Stable disease | 21 (40) | 19 (54) |
| Progression of disease | 7 (13) | 2 (6) |
Response rate according to mutations in codon 12 and 13
| Response rate | Codon 12 mutations, number (%) | Codon 13 mutations, number (%) |
|---|---|---|
| Complete response | 6 (12) | 2 (12) |
| Partial response | 5 (11) | 6 (35) |
| Stable disease | 23 (49) | 7 (41) |
| Progression of disease | 13 (28) | 2 (12) |
Patient’s baseline characteristics
| Patient’s characteristics | Number (%) |
|---|---|
| Medium age (years) | 62 |
| Gender | |
| female | 59 (38) |
| male | 95 (62) |
| WHO performance status | |
| 0 | 36 (23) |
| 1 | 109 (71) |
| 2 | 9 (6) |
| Tumour location | |
| colon | 112 (73) |
| rectum | 42 (27) |
| Primary metastatic | 89 (58) |
| Liver metastases | 68 (44) |
Disease characteristics
| Disease characteristics | Number (%) |
|---|---|
| pT4 of primary tumour | 35 (23) |
| Affected regional lymph nodes (N) | |
| N0 (no affected regional lymph nodes) | |
| N1 (1 to 3 affected regional lymph nodes) | 34 (22) |
| N2 (more than 3 affected regional lymph nodes) | 61 (40) 59 (38) |
| Vascular invasion | 22 (14) |
| Perineal invasion | 25 (16) |
| Lymphangiosis | 27 (17) |
| Grade of differentiation | |
| G1 (well) | 10 (6) |
| G2 (medium) | 131 (85) |
| G3 (poorly) | 13 (8) |
| KRAS gen | |
| non-mutated (wild-type) | 89 (58) |
| mutated | 65 (42) |
| KRAS mutation | |
| codon 12 | 48 (73) |
| codon 13 | 17 (27) |
| BRAF gen | |
| non-mutated (wild-type) | 150 (97) |
| mutated | 4 (3) |
Adverse effects of systemic treatment
| Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) | |
|---|---|---|---|---|
| Haematological | ||||
| leukopenia | 42 (27) | 8 (5) | 1 (1) | |
| neutropenia | 42 (27) | 8 (5) | 1+1 | |
| thrombocytopenia | 33 (21) | 11 (7) | (1+1)* | |
| anaemia | 88 (57) | 10 (6) | ||
| Non-haematological | ||||
| alopecia | 62 (40) | 21 (14) | / | / |
| fatigue | 93 (60) | 11 (7) | 0 | / |
| nausea | 40 (26) | 10 (6) | 0 | / |
| vomiting | 14 (9) | 9 (6) | 0 | 0 |
| diarrhea | 23 (15) | 29 (19) | 2 (2) | 1 (1) |
| stomatitis | 4 (3) | 2 (2) | 0 | 0 |
| hand-foot syndrome | 17 (11) | 6 (4) | 0 | / |
| peripheral sensory neuropathy | 32 (21) | 8 (5) | 0 | 0 |
| hepatic toxicity | 17 (11) | 3 (2) | 0 | 0 |
| renal toxicity | 0 | 0 | 1 (1) | 0 |
| acneiform rash | 14 (9) | 38 (25) | 0 | 0 |
| hypermagnesemia | 6 (4) | 0 | 3 (2) | 0 |
| allergic reaction to cetuximab | 3 (2) | 1 (1) | 0 | 0 |
| allergic reactions to oxaliplatin | 1 (1) | 0 | 0 | 0 |
| arterial hypertension | 3 (2) | 9 (6) | 0 | / |
| proteinuria | 20 (13) | 18 (12) | 0 | 0 |
| bleeding | 6 (4) | 0 | 1 (1) | |
| thromboembolic events | 0 | 7 (5) | 0 | 0 |
| wound complications | 0 | 0 | 0 | / |
| perforation | 0 | 0 | 0 | 0 |
| arthralgia | 17 (11) | 2 (2) | 0 | 0 |
| bladder infection | / | 3 (2) | 0 | 0 |